Herbal Remedies and Nutritional Supplements in the Treatment of Depression: A Review

References

• World Health Organization. WHO traditional medicines strategy 2002–2005. Geneva, Switzerland: World Health Organization; 2002.
   Google Scholar
• Dhingra S, Parle M. Non-drug strategies in the management of depression: A comprehensive study of systematic review and meta-analysis of randomised controlled trials. J Neurosci Behav Health 2011; 3(5): 66–73.
   Google Scholar
• Tierney LM, McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis & Treatment. 45th ed. San Francisco, CA: McGraw-Hill; 2006:1065–66.
   Google Scholar
• Mann JJ. The medical management of depression. N Engl J Med 2005; 353:1819–34.
   PubMed Web of Science ®Google Scholar
• Smith AJ, Sketris I, Cooke C, Gardner D, Kisely S, Tett SE. A comparison of antidepressant use in Nova Scotia, Canada and Australia. Pharmacoepidemiol Drug Saf 2008; 17(7): 697–706.
   Web of Science ®Google Scholar
• Andrews G, Titov N. Depression is very disabling. Lancet. 2007; 370(9590): 808–9.
   Web of Science ®Google Scholar
• Thomas K, Coleman P. Use of complementary or alternative medicine in a general population in Great Britain. Results from the National Omnibus survey. J Public Health (Oxf.) 2004; 26(2): 152–7.
   Google Scholar
• Zhou SF, Lai X. An update of clinical drug interactions with the herbal antidepressant St. John's wort. Curr Drug Metab 2008; 9(5): 394–409.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Soukup J, Davis RB, Foster DF, Wilkey SA, Van Rompay MI, et al. The uses of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry 2001; 158(2): 289–94.
   PubMed Web of Science ®Google Scholar
• Sharma U. Complementary medicine today: practitioners and patients. London, UK: Routledge; 1992.
   Google Scholar
• Fisher P, Ward A. Complementary medicine in Europe. BMJ 1994; 309(6947): 107–11.
   Google Scholar
• Jorm AF, Korten AE, Christensen H, Jacomb PA, Rodgers B, Parslow RA. Association of obesity with anxiety, depression and emotional well being: a community survey. Aust N Z J Public Health. 2003; 27(4): 434–40.
   PubMed Web of Science ®Google Scholar
• Linde K, Berner M, Kriston L. St John's wort for depression (Cochrane Review). In: The Cochrane Library, Issue 4, 2008. London: Wiley.
   Google Scholar
• Pilkington K, Boshnakova A, Richardson J. St John's wort for depression: time for a different perspective? Complement Ther Med 2006; 14(4): 268–81.
   Web of Science ®Google Scholar
• Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, et al. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 2005; 25(5): 441–7.
   PubMed Web of Science ®Google Scholar
• Wurglics M, Lobbert SS, Dingermam T, Schubert-Zsilavecz M. Rational and traditional St. John's wort preparations: Consequences for treatment of depression. Dtsch Apoth Ztg 2003; 143(13): 66–70.
   Google Scholar
• Clement K, Covertson CR, Johnson MJ, Dearing K. St. John's wort and the treatment of mild to moderate depression: a systematic review. Holist Nurs Pract 2006; 20(4): 197–203.
   PubMedGoogle Scholar
• British National Formulary 61. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2011.
   Google Scholar
• Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med. 2002; 136(1): 42–53. Baxter K (ed), Stockley's Drug Interactions 8. [CD-ROM] London: Pharmaceutical Press, 2008.
   Google Scholar
• Farah A. The role of L-methylfolate in depressive disorders. CNS Spectr 2009; 14(1 Suppl 2): S2–S7.
   PubMedGoogle Scholar
• Morris DW, Trivedi M, Rush AJ. Folate and unipolar depression. J. Altern. Complement Med 2008; 14(3): 277–85.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent. CNS Spectr 2007; 12(10): 739–44.
   PubMed Web of Science ®Google Scholar
• Coppen A, Chaudhry S, Swade C. Folic acid enhances lithium prophylaxis. J Affect Disord 1986; 10(1): 9–13.
   Web of Science ®Google Scholar
• Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990; 336(8712): 392–5.
   PubMed Web of Science ®Google Scholar
• Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 2000; 60(2): 121–30.
   PubMed Web of Science ®Google Scholar
• Passeri M, Cucinotta D, Abate G, Senin U, Ventura A, Stramba Badiale M, et al. Oral 5′-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a doubleblind multicenter study. Aging (Milano) 1993; 5(1): 63–71.
   Google Scholar
• Freeman MP. Omega-3 fatty acids in major depressive disorder. J Clin Psychiatry 2009; 70(Suppl 5): S7–S11.
   PubMed Web of Science ®Google Scholar
• Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007; 68(7): 1056–61.
   PubMed Web of Science ®Google Scholar
• Freeman MP. Omega-3 fatty acids and perinatal depression: a review of the literature and recommendations for future research. Prostaglandins Leukot. Essent. Fatty Acids 2006; 75(4–5): 291–7.
   Web of Science ®Google Scholar
• Kris-Etherton PM, Harris WS, Appel LJ; Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23(2): 20–30.
   PubMed Web of Science ®Google Scholar
• Appleton KM, Hayward RC, Gunnell D, Peters TJ, Rogers PJ, Kessler D, Ness AR. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr 2006; 84(6): 1308–16.
   PubMed Web of Science ®Google Scholar
• Harris WS. Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am. J. Cardiol. 2007; 99(6A): 44–6.
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Alpert JE, Fava M. S-adenosyl-methionine in depression: a comprehensive review of the literature. Curr Psychiatry Reports 2003; 5(6): 460–6.
   Google Scholar
• Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for treatment of major depressive disorder. J Clin Psychiatry 2009; 70(Suppl 5): S18–S22.
   PubMed Web of Science ®Google Scholar
• Thomas CS, Bottiglieri T, Edeh J, Carney MW, Reynolds EH, Toone BK. The influence of S-adenosylmethionine (SAM) on prolactin in depressed patients. Int Clin Psychopharmacol 1987; 2(2): 97–102.
   Web of Science ®Google Scholar
• Bottiglieri T, Godfrey P, Flynn T, Carney MW, Toone BK, Reynolds EH. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 1990; 53(12): 1096–8.
   PubMed Web of Science ®Google Scholar
• Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability or oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr 2002; 76(Suppl): 1172S–S6.
   Google Scholar
• Fava M, Rosenbaum JF, Birnbaum R, Kelly K, Otto MW, MacLaughlin R. The thyrotropin response to thyrotropin-releasing hormone as a predictor of response to treatment in depressed outpatients. Acta Psychiatr Scand 1992; 86(1): 42–5.
   Web of Science ®Google Scholar
• Taylor MJ, Wilder H, Bhagwagar Z, Geddes J. Inositol for depressive disorders (Cochrane Review). In: The Cochrane Library, Issue 2, 2004. London: Wiley.
   Google Scholar